Autologous Anti-gp100 154-162 TCR Gene-engineered PBL

Cancer Terms -> Drugs and Chemicals -> Pharmacologic Substance -> Biological Agent -> Autologous Lymphocytes -> Autologous Anti-gp100 154-162 TCR Gene-engineered PBL

Autologous Anti-gp100 154-162 TCR Gene-engineered PBL Definition

Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas.

Autologous Anti-gp100 154-162 TCR Gene-engineered PBL Synonyms

Autologous Anti-gp 100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes, Anti-p53 TCR-Transduced PBL, Autologous Anti-gp100:154-162 TCR Gene-Engineered PBL

Autologous Anti-gp100 154-162 TCR Gene-engineered PBL

Autologous Anti-gp100 154-162 TCR Gene-engineered PBL Definition

Autologous Anti-gp100 154-162 TCR Gene-engineered PBL Synonyms

Terms in Autologous Anti-gp100 154-162 TCR Gene-engineered PBL category